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Abstract  
  
Background: Differential prognostic roles of Androgen Receptor (AR) have been proposed 
in breast cancer (BC) depending on tumour oestrogen receptor (ER) status. This study aimed 
to evaluate the prognostic and/or predictive significance of androgen receptor (AR) 
expression in invasive BC.  
Methods: In this study AR expression was studied on a large (n=1141) consecutive series of 
early-stage (I-III) BC using tissue microarray and immunohistochemistry (IHC). AR mRNA 
expression was assessed in a subset of cases. The prognostic impact of AR mRNA expression 
was externally validated using the online BC gene expression data sets (n=25 data sets, 4,078 
patients).  
Results: Nuclear AR IHC expression was significantly associated with features of good 
prognosis including older age, smaller tumour size, lower grade and lobular histology 
particularly in the ER-positive tumours. AR was associated with ER-related markers GATA3, 
FOXa1, RERG and BEX1. Negative association was observed with HER2, p53, Ki67, TK1, 
CD71 and AGTR1. AR Overexpression was associated with longer survival (p <0.001), 
independent of tumour size, grade, stage (p=0.033, hazard ratio (HR) =0.80 95%CI=0.64-
0.98). Similar associations were maintained in ER+ tumours in univariate and multivariate 
analysis (p<0.01) both in patients with and without adjuvant endocrine or chemotherapy. AR 
mRNA expression showed significant association with tumour grade, molecular subtypes, 
and longer 10 and 15 years survival in luminal BC. In the external validation cohorts, AR 
gene expression data was associated with improved patients’ outcome (p<0.001, HR=0.84, 
95% CI 0.79-0.90).   
In conclusion: AR is an independent prognostic factor in ER-positive luminal breast cancer 
but is also expressed in ER-negative tumours. AR could act as a molecular target in patients 
with ER-positive disease predicting response to adjuvant therapy.   
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Introduction 
Androgen receptor (AR), similar to oestrogen receptor (ER) and progesterone receptor (PR), 
belongs to the steroid nuclear receptor family (nuclear receptor 3, group C, member 4; 
NR3C4) [1, 2]. AR is activated when bound by its specific ligands which results in 
conformational receptor changes and then receptor translocation into the nucleus where it 
undergoes dimerisation. The dimer binds to its specific Hormone Receptor Elements (HREs) 
[3].  The AR functions mainly as a DNA-binding transcription factor that regulates gene 
expression [4]. In-vitro cell lines studies revealed that AR potently inhibits ER transactivation 
and proliferation and promotes apoptosis [5, 6].  However the interaction between AR and 
ER remains unclear. It has been suggested that signalling through AR replaces oestrogen-
dependent signalling and exerts a stimulatory effect through the androgen responsive 
element, thereby stimulating transcription of steroid responsive genes [7].  
 
In breast cancer (BC), AR is expressed in 50-88% of cases [8-14] with an average of 61% in 
all BCs and 75% in ER-positive tumours [15].  Previous studies have shown that AR 
expression has the potential to predict disease progression [15, 16], as well as the likelihood 
and duration of response to therapy when used with medroxyprogesterone acetate [17]. It was 
shown that reduced AR expression can predict a four-fold increase in the risk of BC related 
death in ER-positive BC patients [5]. Studies of ER-negative and triple negative (TN) BC 
report conflicting results regarding the prognostic significance of AR with some authors 
indicating a good prognostic value[18] while others reported it is associated with worse 
outcome [14]. Molecular classification of BC has also reported the identification of a 
molecular apocrine class that is characterised by loss of ER expression but with expression of 
AR and activation of androgen signalling.  In a meta-analysis, AR was associated with 
favourable prognosis of BC irrespective of ER expression [15].  
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Although AR is the main biological driver and therapeutic target in prostate cancer patients, 
its therapeutic targeting has been found to pose an anti-proliferative action in BC patients 
[19]. The use of androgens as hormonal therapy in BC has shown results that are generally 
comparable to Tamoxifen [20, 21]. For instance, fluoxymesterone, an androgen agonist, was 
studied in advanced BC patients decades ago with reported therapeutic responses of 14-53% 
[22-24]. Taken together, this study aimed at assessing the prognostic and predictive 
significance of AR expression (protein and mRNA) in BC patients with emphasis on BC 
molecular subtypes.  
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Materials and Methods 
 
This study was based on:  
I: A retrospective cohort comprising a well characterised series of early invasive (TNM Stage 
I-III, excluding T3 and T4 tumours) primary operable BC patients presented to Nottingham 
City Hospital from 1987-1997. Tumours in these patients were 5 cm in diameter or less at 
time of presentation [25]. Patients were uniformly treated according to standard protocol; 
primary surgery, with either mastectomy or wide local excision, followed by radiotherapy. 
Before 1989, patients did not receive systemic adjuvant therapy. After 1989, the adjuvant 
treatment stratification of the patients in this cohort was based on prognostic and predictive 
factors including hormone receptor (ER) status, menopausal state and Nottingham Prognostic 
Index (NPI). Patients with good prognostic index (NPI <3.4) were considered low risk and 
did not receive adjuvant systemic therapy. Pre-menopausal women with an NPI >3.4 (high 
risk) received classical cyclophosphamide, methotrexate and 5-flurouracil (CMF) 
chemotherapy and patients with ER-positive tumours were offered hormone therapy (HT). 
Post-menopausal women with an NPI score >3.4 and ER-positivity were offered HT whilst 
ER-negative patients were offered classical CMF chemotherapy [26] 
 
Patients’ clinical and pathological data including age, histological tumour type, primary 
tumour size, lymph node status, histological status, NPI [27], and vascular invasion were 
available and prospectively maintained. This cohort has been well investigated using a wide 
range of biological markers of close relevance to BC biology and outcome. These markers 
include AR (previously stained in this cohort using anti-AR primary antibody, clone F39.4.1, 
Biogenex, UK, and the Streptavidin-Biotin ”ABC” secondary detection method) [25], ER, 
PR, HER2, cyokeratins (Ck), Cyclin B1, Ki67, and P53. For further insight into the 
relationship between ER and AR (i.e. ER-AR interaction), the ER-related proteins including 
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FOXa1, GATA3, BEX1, PELP1, RERG, and TK1 were also used in this analysis. Survival 
data includes Breast Cancer Specific Survival (BCSS), in months, from the date the primary 
surgical treatment to the time of death from breast cancer. Distant metastasis free interval 
(DMFI) was defined as the time, in months, taken from primary surgical treatment to the first 
distant recurrence. The duration of follow-up for this study was 306 months and the (mean 
survival = 150, median was 167 months, with 1136 patients had survival data at the end of 
follow-up time. Clinicopathological data of this series is presented in supplementary Table 1). 
A subset of this cohort (n=284) was included in the multicentre study; the Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) study, for which the 
human genome has been characterised. For this subset, mRNA was extracted from fresh 
frozen tumours and hybridised to Illumina HT-12 v3 platform (Bead Arrays) and the data 
were pre-processed and normalised as previously described [28]. The AR mRNA expression 
was investigated in this subset. Correlation co-efficient was used to test for association 
between AR immunohistochemical (IHC) expression and AR mRNA expression data, while 
appropriate statistical tests were used to test for association with clinicopathological variables 
as well as patients’ outcome. This research was approved by Nottingham Research Ethics 
Committee 2 under the title of ‘‘Development of a molecular genetic classification of breast 
cancer’’. All cases included in this study were from patients who were consented prior to 
inclusion in the study cohort. 
This study adheres to REporting recommendations for tumour MARKer prognostic studies 
(REMARK) criteria [29] 
Immunohistochemistry (IHC)  
Validating the antibody specificity:  
Prior to IHC, the specificity of the anti-AR primary antibody (Sc-816, Santa Cruz 
Biotechnology, UK) was validated using Western blotting (WB). WB was performed on 
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whole cell lysates of MCF-7 and MDA-MB 231 human BC cell lines (obtained from the 
American Type Culture Collection; Rockville, MD, USA) using 1:100 dilution of the primary 
antibody dilution, and 1:2,000 of the HRP labelled secondary anti-rabbit antibody, as 
previously described [30]. This showed a single specific band at the predicted size (110 KDa) 
of AR protein, confirming the specificity of the antibody (Figure 1A). 
Procedure of Immunohistochemistry 
IHC was applied to tissue microarrays (TMA) using Novolink™ Max Polymer Detection 
System from Leica Biosystems (Leica, Newcastle, UK). Heat induced retrieval of antigen 
epitopes was performed in citrate buffer (pH 6) using microwave for 20 minutes. Anti-AR 
primary antibody (Sc-816, Santa Cruz Biotechnology, UK) was applied, diluted at 1:40, for 
60-minutes incubation. For reaction visualisation, 3-3’ Diam-inobenzidine tetrahydrochloride 
(Novolink DAB substrate buffer plus) was used as a chromogen. Negative (primary antibody 
replaced by Phosphate-buffered saline (PBS) and positive controls (FFPE tissue section of a 
known AR positive BC case) were included in the staining run.  
 
Assessment of IHC staining  
Slides were scanned into high resolution digital images (0.45µm/pixel) using a NanoZoomer 
slide scanner (Hamamtsu Photonics, Welwyn Garden City, UK) and uploaded into web 
server where they could be accessed using a web based interface (Distiller, Leica). TMA 
cores were scored at 20x magnification using a minimum of 24” high resolution computer 
screen (1920x1080).  The semi-quantitative immunohistochemical scoring (H-score) method 
was used, which takes the intensity and percentage of stained invasive tumour tissue stained 
into account [31].  All cases were scored without prior knowledge of the patients’ pathologic 
or outcome data. Although, cytoplasmic staining was observed in some TMA cores, only 
nuclear staining was considered in this study. 
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Breast cancer molecular subtypes were defined based on their IHC expression profile into: 1) 
luminal/hormone receptor (HR)+; ER+ and/or PR+, 2) HER2+ (HER2+ regardless of the 
expression of other markers), 3) Triple negative basal-like; ER-, PR-, HER2-, and positive for 
CK5/6, and/or CK14 and/or EGFR and 4) triple negative non-basal BC; all above  markers 
negative), as previously described [32] 
II: External validation cohorts: For external validation of AR mRNA expression, bc-
GenExMiner v3.0 (Breast Cancer Gene-Expression Miner v3.0) online dataset 
(http://bcgenex.centregauducheau.fr) was used. In this study, the "prognostic module", 
offering the possibility to evaluate the prognostic impact of candidate genes in breast cancer, 
was used [33]. Cox model, Kaplan–Meier and forest plots were generated. 
 
Statistical Analysis 
The statistical analysis was performed using Statistical Package for Social Sciences SPSS 
version 21 for Windows (SPSS Inc., Chicago, IL, USA). A p value (two-tailed) of less than 
0.05 was considered significant. Spearman correlation co-efficient was used to test for 
correlation between continuous variables. Cut-off values for the different biomarkers 
included in this study were chosen before statistical analysis. Standard cut-offs were used for 
established prognostic factors and were the same as for previously published patient series 
[32]. Determination of the optimal AR H-score cut-offs was obtained using X-tile bio-
informatics software [34]. Analysis of categorical variables was performed using the 
appropriate statistical test. Kaplan-Meier plots were used to visualise the survival distribution 
of dichotomised AR, with differences in survival estimated using Log-rank tests. Multivariate 
Cox proportional hazards model was fitted to adjust for confounders and test statistical 
independence of AR in predicting BCSS and DMFS.  
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Results 
 
I: AR IHC results:  
 
The number of BC cases informative on the TMA for AR expression in this study was 1141. 
Figure 1 B, C & D displays representative images of the tumour tissue cores with varying 
degrees of AR staining.  
The distributions of AR H-scores did not follow normal distribution. Optimum cut-off point 
for AR expression, as defined by X-tile software using BCSS as endpoint, was set at H score 
= 190. This cut-off point was used to categorise cases into AR negative/low (H-score <190; 
n=528/1141, 46.3%) and AR positive/high (H-score ≥190; n=613/1141, 53.7%) expression. 
 
 
Associations of AR IHC expression with clinicopathological features and other markers  
Nuclear expression of AR showed positive association with patients’ age (p <0.001) and 
pathological features of good prognosis including smaller tumour size (p=0.001), lower 
histological grade, more tubule formation, less pleomorphism and low mitotic counts, lobular 
histological type and special tumour types of excellent prognosis, and low NPI score 
(p<0.001). Negative association was observed with tumours of medullary-like histology. 
Importantly, AR expression was negatively associated with mitosis in the whole series, 
irrespective of ER status. Within the whole series, AR was positively associated with luminal 
enriched proteins FOXa1, GATA3, BEX1, PELP1, and RERG, while negative association 
was observed with the HER2+ status (p=0.003), P53 status, Ki67LI, and CD71 (p<0.001). 
AR was associated with BC molecular intrinsic subtypes as defined by IHC surrogate 
markers [32]  (p < 0.001, and p= 0.034, for the whole series and ER+ tumours, respectively; 
Table 2). Highest AR expression was observed in luminal tumours (499/778, 64.1%), while it 
was less expressed in HER2+ and TN Basal-like, while the TN-non-Basal BC showed the 
least AR expression (59/142, 41.5%, 33/142, 23.2% and 5/48, 10.4%, respectively). 
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Moreover, within ER+/luminal tumours, AR was positively associated with ER-related and 
luminal-enriched genes including, AGTR1 (p= 0.014), PELP1 (p= 0.026), CARM1 (p= 
0.008), CD71 (p < 0.016), FOXa1, (p <0.001), GATA3 (p <0.001), BEX1 (p <0.001), and 
RERG (p= 0.002).  Only TK1 was significantly associated (p = 0.011) with AR in the ER- 
tumours (Table 2).   
 
Associations of AR with patients’ outcome  
High expression of AR was associated with longer BCSS (Log rank (LR) = 17.88, p <0.001; 
Figure 2A). In ER-positive tumours, higher AR levels were predictive of longer BCSS 
(LR=14.58; p <0.001; Figure 2B). Cox proportional multivariate analysis showed that higher 
AR level of expression was an independent indicator of better outcome irrespective of tumour 
size, grade and nodal stage (p = 0.033, hazard ratio (HR) = 0.80 95% CI = 0.64-0.98; Table 
3). Multivariate analysis showed that AR is an independent prognostic marker (p=0.007, HR 
= 0.71 95% CI = 0.56-0.91; Table 3). However, inclusion of Ki67LI into the cox proportional 
hazard model rendered AR expression insignificant (p=0.255, and p=0.091, for the whole 
series and luminal type, respectively).  
Regarding distant metastasis, there was an association between low levels of AR expression 
and probability of development of DM (LR = 23.32; p < 0.001), Figure 2C. This relationship 
was maintained using a Cox regression model which showed that AR was an independent 
predictor of longer DMFI (HR=0.80; p=0.034; 95% CI = 0.65-0.98). A similar association 
was also observed in the luminal subgroup (Figure 2D). Inclusion of Ki67LI into the cox 
proportional hazard model rendered AR expression statistically insignificant (p = 0.690, and 
p = 0.550, for the whole series and luminal type, respectively).  
 
The favourable prognostic significance of AR expression was evident in ER-positive patients 
regardless of their hormonal therapy status. Patients who received, as well as those who did 
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not receive hormonal therapy (HT), showed significant survival advantage in the AR-positive 
group, Figures 3A and 3B, respectively. Considering adjuvant chemotherapy, the prognostic 
advantage of positive AR expression was maintained in patients with ER-positive disease 
who either received or did not receive adjuvant chemotherapy (LR= 4.62, p = 0.032, LR= 
8.06, p = 0.005, respectively, Figures 3C and 3D). Using X-tile, AR was able to stratify BC 
patients into three prognostic groups; those with AR expression level less than 200 H-score 
had shorter 15-year BCSS compared to both intermediate-risk group (200-260) and least-risk 
group (>260) (LR = 18.78; p <0.001).  
 
When the analysis was restricted to the TNBC and HER2+ phenotypes, nuclear AR 
expression was neither associated with BCSS nor with DMFI even when using different cut-
off point for dichotomisation of AR expression (data not shown).  
 
II: AR mRNA expression  
AR mRNA expression was assessed in a subset of cases that were included in the 
METABRIC study [35] (n=284 cases). This showed a significant positive correlation 
between AR protein IHC expression and AR mRNA expression (r=0.424, p<0.001).  AR 
mRNA showed significantly higher expression in low grade tumours (One-way ANOVA (F), 
=5.046, p = 0.007) with low proliferative activity as assessed by mitotic scores (F= 8.056, p < 
0.001) and Ki67LI (r=0.403, p < 0.001).  
Significant differences were observed between BC molecular subtypes (F= 29.361, p < 
0.001), with highest expression observed in the luminal/ER+ subtype. Within the 
luminal/ER+ tumours using the median cut-off, high AR mRNA expression showed longer 
BCSS as compared to low expression, at 10 and 15 of follow-up with a trend towards 
significant association at 20 years of follow-up (data not shown).     
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B: External validation cohorts 
Using bc-GenExMiner v3.1 (Breast Cancer Gene-Expression Miner v3.1) online dataset as 
external validation cohorts, the prognostic impact of AR mRNA expression was investigated. 
As shown in the Forest plot (Supplementary Figure 1), 25 datasets were investigated. In 5/25 
studies, high AR mRNA expression was significantly associated with improved survival, in 
one dataset (n=155 patients) it was significantly associated with shorter survival, while the 
rest of data sets did not show significant association with outcome (Supplementary Table 2). 
When data of all datasets was pooled together (n=4,078), high AR mRNA expression was 
significantly associated with better metastatic recurrence (MR) free survival (p<0.001, 
HR=0.78, 95%CI 0.69-0.88; Supplementary Figure 1). This association was maintained in 
the ER-positive datasets (p= 0.0017, HR = 0.78, 95%CI 0.67 - 0.91). However, associations 
of AR with improved outcome deemed statistically insignificant when the analysis was 
adjusted for proliferation both in the whole and ER-positive datasets (n=2,528 patients, p= 
0.8824 and n= 1,907, p = 0.6654, respectively).   
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Discussion:  
 
Despite being an important member of the steroid receptor superfamily, its frequent 
expression in BC and its relation to ER, the biological and clinical significance of AR 
remains under investigation.  Although multiple authorities have reported a good prognostic 
impact of AR expression in BC [36, 37], others have described that patients with AR over-
expressing ER-negative BC have shorter survival [38]. Molecular apocrine class, which is 
characterised by AR expression and pathway activation typically lacks ER expression and is 
associated with poor prognosis. Moreover, the magnitude of AR expression impact on 
outcome has been variably reported in different BC molecular subtypes and whether it is 
dependent on ER or proliferation remains to be defined. In addition, the correlation between 
AR mRNA and AR protein expression and the clinical significance of each remains to be 
characterised.  
 
In this study, there was high prevalence of AR expression, more than ER and PgR expression, 
with those cases showing complete absence of AR forming a minority of cases. This goes in 
line with previous reports [39, 40]. Interestingly, in studies that have utilised smaller number 
of patients, it has been shown that AR is frequently expressed in some special types of 
invasive BC more than others such as apocrine and invasive lobular carcinoma [41-44]. Our 
study supports these findings and demonstrates that AR expression is significantly higher in 
invasive lobular carcinoma as well as other special histologic types of excellent prognosis. 
These associations were significant in the whole series, ER+, and ER- subgroups.  
 
Consistent with previous studies [18, 45, 46], our results showed an association between AR 
expression features of good prognosis including older patient age, small tumour size, lower 
tumour grade with lower proliferative activity as well as hormone receptor positivity. The 
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interaction between AR and ER in down-regulation cancer cell proliferation has led some 
authorities to speculate that combined selective estrogen/androgen hormone modulators may 
be an alternative promising modality to the current modalities in hormone receptor positive 
BC [47, 48]. In this study, luminal BC showed the highest expression of AR compared to 
HER-positive and TN tumours. Moreover, AR was associated with markers known to be 
regulated via ER and more expressed in luminal BC such as GATA3, FOXa1, CARM1, 
RERG, PELP1, AGTR1, CD71, and BEX1. From these results, it appears that AR prognostic 
value of expression varies significantly depending on the ER status of the tumour. In line 
with notion, it has been suggested that the dependency of AR on ER status is related to the 
competitive interaction between AR and ER [5], where in the presence of the latter, AR 
interacts with oestrogen response elements on ER, blocking downstream oestrogen target 
genes, leading to inhibition of ER stimulated tumour proliferation. Contrasting this, when ER 
is lacking/absent, AR interacts with AR elements and promotes tumour cell growth [49]. In 
line with this is the report of Elebro and co-authors who reported on the interaction of AR 
and ER in determining the impact of AR expression [50].   
 
Regarding the association with patients’ outcome, AR overexpression was shown to be 
significantly associated with improved outcome in the whole series and in ER-positive BC. 
These associations were independent of other well-established prognostic variables including 
tumour size, grade and nodal stage. However, this prognostic advantage of AR expression 
was lost upon inclusion of proliferative fraction, as assessed by Ki67LI, into the multivariable 
model, indicating dependency of AR on tumour proliferation.  
In this study, AR mRNA expression showed a positive correlation with AR protein 
expression. Consistent with AR protein expression, higher AR mRNA expression was 
observed in low grade tumours, and was differentially expressed in BC molecular subtypes, 
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with highest was observed in the luminal/ER-positive subtype conferring better outcome as 
compared to low expression both as early as late during follow-up period (at 10 and 15 
years). Furthermore, 25 online datasets were investigated for AR mRNA expression as 
external validation cohorts. Significantly longer distant recurrence free survival was observed 
with high AR mRNA expression both in unselected (n=4,078) and ER-positive datasets. Once 
again, these associations deemed statistically insignificant upon adjustment for proliferation 
in the whole datasets and in ER+ datasets. Therefore, AR prognostic significance appears to 
be highest in ER+ low proliferative tumours; results in line with AR IHC in our BC series.   
It is noteworthy that the improved outcome of high AR IHC expression was maintained in 
patients received adjuvant hormonal or chemotherapy, or did not receive adjuvant therapy. In 
both instances of adjuvant therapy, patients with AR positive tumours performed better than 
those with AR negative tumours. Therefore, adjunctive therapeutic manipulation of AR, with 
or without other therapies, could be useful in improving outcome, especially in 
chemotherapy-intolerant patients. Moreover, not only the status of AR as assessed by IHC 
which could stratify patients, but the level of AR expression was also useful in distinguishing 
three distinct prognostic groups in BC. Cases which expressed highest levels of AR survived 
the longest while those with tumours expressed lowest AR levels survived significantly 
shorter periods. This finding can have useful implications on treatment selection for specific 
AR expression subgroups of BC patients. 
TNBC are regarded as a heterogeneous subtype of BC with chemotherapy as the mainstay of 
treatment for both early stage and advanced invasive TNBC. In this study 20% of TNBC 
showed overexpression of AR at H score = 190 cut-off point. However, 85% of cases of 
TNBC expressed AR showing 1% or more of staining. Accordingly; AR expression was not 
only expressed in the ER+/luminal tumours but also in the TNBC. However, it was not 
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significantly associated with patients’ outcome in the TNBC neither in the basal phenotype 
tumours at cut-off point used for the whole series and the ER+ subgroup nor with other cut-
offs. Current studies are investigating novel therapeutic strategies in phase II and phase III 
clinical trials. The anti-androgens for AR positive TNBC are amongst those molecularly 
targeted therapies currently being tested [51]. Although findings in our data did not show 
prognostic significance of AR in TNBC, this does not preclude the potential utility of AR 
molecular targeted therapies for TNBC tumours. It is worth mentioning that variable results 
of AR expression in literature, both in unselected and different intrinsic molecular subtypes, 
could be attributed to many reasons. These include the inherent heterogeneous nature of 
invasive BC, intratumoural heterogeneity of AR expression, using different antibody clones 
or secondary detection kits with variable sensitivity, or inter-observer variability in 
interpreting the IHC staining. In our study, the overall agreement between the used antibody 
in this study and a previously used clone [32] showed excellent agreement. Moreover, it 
produced the same associations with clinicopathological, biomarker and patients’ outcome 
(data not shown).  
 
The use of such therapy stands as a potential avenue especially in case of treatment 
failure/resistance with the currently used chemotherapeutic regimens [52, 53]. Meanwhile, 
several issues that surround the expression of AR in BC should be addressed, such as its 
relationship with the HER2-pathway, and most importantly if the receptor expressed in BC is 
different from ARs expressed in other tissues of the body [54, 55]. Should similarities be 
present, they will be critical to minimise any potential side effects associated with any future 
AR-targeted therapy. 
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In conclusion, AR is abundantly expressed in invasive BC with significant association with 
favourable prognostic parameters both at protein and transcriptomic levels. It is an 
independent prognostic factor and can further stratify the patient into distinct prognostic 
subgroups significantly different in outcome. There is interaction between AR and ER and 
proliferation which may explain the differential prognostic effect of AR in BC. 
Understanding these biological interactions may help in utilising AR as a molecular 
therapeutic target in invasive BC.  
 
 
 
 
 
 
Acknowledgment:  
MA Aleskandarany and Maria Diez-Rodriguez are funded by the University of Ha’il, KSA.  
 
 
 
 
Conflict of interest: The authors have no conflicts of interest to declare.  
 
 
 
 
 
 
 
 
 
18 
 
Titles and legends to figures 
 
Figure 1: Western Blotting (WB) of AR antibody and IHC expression in invasive BC 
TMA:  
A) WB on whole cell lysates of MCF-7 and MDA-MB 231 human BC cell lines using 
anti-AR primary antibody (Sc-816, Santa Cruz, UK) 1:100 dilution of the primary 
antibody dilution, and 1:2,000 of the HRP labelled secondary anti-rabbit antibody. 
Immunohistochemical expression of AR in invasive BC: B) negative AR; C) weak to 
moderate AR expression; and D) Strong AR expression.  
 
 
 
Figure 2: Kaplan Meier plot for the association of AR nuclear expression in relation to 
BCSS and metastasis free survival: 
A) in the whole series; B) in ER-positive tumours. C) Distant metastasis free survival in 
patients expressing AR in the whole series, and D) in ER+ tumours.  
 
 
Figure 3: Kaplan Meier plot for the association of AR nuclear expression in relation to 
Adjuvant therapy:  
A) Patients with no hormonal therapy (HT), B) Patients who received HT. C: Patients 
received adjuvant chemotherapy, and D) patients who did not receive adjuvant 
chemotherapy.  
 
Supplementary Figure 1: A) Forest plot of AR mRNA expression impact on patients’ 
outcome in the 25 external validation cohorts. B) Association of AR mRNA expression in the 
external validation cohorts with patient outcome (= 4078 patients) 
  
19 
 
Tables legends:  
Table 1: Correlations between AR expression and clinico-pathological features in the whole 
series and in ER-positive BC 
 
Table 2: Association between AR and the expression of other markers in the whole series 
and in ER-positive BC 
 
Table 3: Cox proportional hazard analysis for predictors of BCSS within the whole studied 
series and within ER+ tumours only.  
 
Supplementary Table 1: Clinico-pathological features of the study cohort 
 
 
 
Supplementary Table 2: The prognostic impact AR mRNA in the external validation cohorts 
using bc-GenExMiner v4.0 for publicly available online datasets (n=25 datasets, 4078 
patients).   
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Table 1: Associations between AR expression and clinico-pathological features in the whole series and in ER-positive BC 
 AR Expression in the whole series AR Expression in the ER-Positive tumours AR Expression in the ER-Negative tumours 
 Negative/low N 
(%) 
Positive/high 
N (%) 
p-value(χ2) Negative/low N 
(%) 
Positive/high N 
(%) 
p-value(χ2) Negative/low N 
(%) 
Positive/high N 
(%) 
p-value(χ2) 
Age 
<40 
40-49 
50-59 
≥60 
 
60 (63.8) 
147 (47.0) 
171 (48.4) 
147 (39.2) 
 
34 (36.2) 
166 (53.0) 
182 (51.6) 
228 (60.8) 
 
 
<0.001 (19.93) 
 
21 (45.7) 
82 (35.7) 
108 (41.2) 
101 (32.9) 
 
25 (54.3) 
148 (64.3) 
154 (58.8) 
206 (67.1) 
 
 
0.118 (5.88) 
 
39 (81.3) 
64 (80.0) 
62 (69.7) 
44 (69.8) 
 
9 (18.8) 
16 (20.0) 
27 (30.3) 
19 (30.2) 
 
 
0.235 (4.25) 
Menopausal Status 
Pre- 
Post- 
 
215 (48.6) 
307 (44.9) 
 
227 (51.4) 
377 (55.1) 
 
0.222 (1.53) 
 
106 (35.2) 
206 (38.3) 
 
195 (64.8) 
332 (61.7) 
 
0.377 (0.78) 
 
107 (78.7) 
100 (70.4) 
 
29 (21.3) 
42 (29.6) 
 
0.115 (2.49) 
Tumour Size (cm) 
≤2.0 
> 2.0 
 
226 (41.3) 
300 (51.2) 
 
321 (58.7) 
286 (48.8) 
 
0.001 (11.10) 
 
149 (33.8) 
163 (40.4) 
 
292 (66.2) 
240 (59.6) 
 
0.045 (4.01) 
 
73 (74.5) 
137 (75.3) 
 
25 (25.5) 
45 (24.7) 
 
0.885 (0.02) 
Stage 
1 
2 
3 
 
318 (46.2) 
154 (44.9) 
52 (53.1) 
 
371 (53.8) 
189 (55.1) 
46 (46.9) 
 
 
0.354 (2.07) 
 
188 (36.4) 
96 (36.6) 
26 (40.6) 
 
328 (63.6) 
166 (63.4) 
38 (59.4) 
 
 
0.805 (0.44) 
 
126 (76.4) 
58 (72.5) 
26 (76.5) 
 
39 (23.6) 
22 (27.5) 
8 (23.5) 
 
 
0.794 (0.46) 
Tumour Type 
Ductal NST 
Lobular 
Tubular mixed  
Medullary-like 
Special types * 
Mixed NST and Lobular 
Mixed NST and other 
special type 
 
350 (52.2) 
30 (27.8) 
67 (34.2) 
23 (92.0) 
10 (20.0) 
19 (43.2) 
12 (60.0) 
 
 
321 (47.8) 
78 (72.2) 
129 (65.8) 
2 (8.0) 
40 (80.0) 
25 (56.8) 
8 (40.0) 
 
 
 
 
 
<0.001 (72.35) 
 
173 (39.8) 
30 (28.6) 
62 (33.2) 
2 (66.7) 
8 (17.8) 
18 (43.9) 
12 (63.2) 
 
262 (60.2) 
75 (71.4) 
125 (66.8) 
1 (33.3) 
37 (82.2) 
23 (56.1) 
7 (38.6) 
 
 
 
 
0.002 (20.53) 
 
177 (74.4) 
0 (0.0) 
5 (62.5) 
21 (95.5) 
1 (50.0) 
1 (33.3) 
0 (0.0) 
 
59 (25.3) 
2 (100) 
3 (37.5) 
1 (4.5) 
1 (50.0) 
2 (66.7) 
1 (100) 
 
 
 
 
0.006 (18. 08) 
Grade 
1 
2 
3 
 
53 (29.1) 
120 (32.1) 
351 (61.1) 
 
129 (70.9) 
254 (67.9) 
223 (38.9) 
 
 
<0.001 (102.88) 
 
50 (29.1) 
107 (30.6) 
153 (47.8) 
 
122 (70.9) 
243 (69.4) 
167 (52.2) 
 
 
<0.001 (26.94) 
 
1 (20.0) 
12 (57.1) 
197 (77.9) 
 
4 (80.0) 
9 (42.9) 
56 (22.1) 
 
 
0.002 (12.83) 
Tubules 
1 
2 
3 
 
19 (29.2) 
135 (38.5) 
352 (51.5) 
 
46 (70.8) 
216 (61.5) 
332 (48.5) 
 
 
<0.001 (23.60) 
 
18 (30.0) 
107 (34.6) 
173 (38.4) 
 
42 (70.0) 
202 (65.4) 
277 (61.6) 
 
 
0.318 (2.29) 
 
0 (0.0) 
28 (70.0) 
179 (76.8) 
 
3 (100.0) 
12 (30.0) 
54 (23.2) 
 
 
0.007 (9.95) 
Pleomorphism 
1 
2 
3 
 
12 (41.4) 
124 (29.9) 
367 (56.2) 
 
17 (58.6) 
291 (70.1) 
286 (43.8) 
 
 
<0.001 (71.05) 
 
11 (44.0) 
115 (29.0) 
170 (42.9) 
 
14 (56.0) 
281 (71.0) 
226 (57.1) 
 
 
<0.001 (17.21) 
 
0 (0.0) 
9 (52.9) 
197 (77.0) 
 
2 (100.0) 
8 (47.1) 
59 (23.0) 
 
 
0.004 (10.91) 
Mitosis 
1 
2 
3 
 
107 (27.9) 
82 (39.8) 
317 (62.0) 
 
276 (72.1) 
124 (60.2) 
194 (38.0) 
 
 
<0.001 (106.38) 
 
101 (27.6) 
64 (36.6) 
133 (47.8) 
 
265 (72.4) 
111 (63.4) 
145 (52.2) 
 
 
<0.001 (27.98) 
 
5 (38.5) 
18 (60.0) 
184 (79.0) 
 
8 (61.5) 
12 (40.0) 
49 (21.0) 
 
 
0.001 (14.82) 
LVI 
Negative 
Definite 
 
340 (46.0) 
182 (46.9) 
 
399 (54.0) 
206 (53.1) 
 
0.774 (0.08) 
 
202 (36.5) 
108 (37.6) 
 
351 (63.5) 
179 (62.4) 
 
0.753 (0.10) 
 
135 (75.4) 
74 (74.0) 
 
44 (24.6) 
26 (26.0) 
 
0.793 (0.07) 
NPI 
GPG 
MPG 
PPG 
 
102 (30.4) 
313 (51.7) 
111 (57.8) 
 
234 (69.6) 
292 (48.3) 
81 (42.2) 
 
 
<0.001 (51.75) 
 
92 (29.4) 
167 (40.0) 
53 (46.5) 
 
221 (70.6) 
250 (60.0) 
61 (53.5) 
 
 
0.001 (13.48) 
 
7 (46.7) 
145 (77.5) 
58 (74.4) 
 
8 (53.3) 
42 (22.5) 
20 (25.6) 
 
 
0.029 (7.08) 
NPI: Nottingham Prognostic Index, GPG; Good Prognostic Group; MPG: Moderate Prognostic Group; PPG: Poor Prognostic Group; LVI: Lympho-Vascular Invasion 
*: include invasive mucinous, invasive cribriform invasive tubular and invasive papillary carcinomas.  
 
Table 2: Association between AR and the expression other markers in the whole series and in ER-positive BC 
 AR Expression in the whole series AR Expression in the ER-Positive tumours AR Expression in the ER-Negative tumours 
 Negative/low N (%) Positive/high N (%) p-value (χ2) Negative/low N (%) Positive/high N (%) p-value (χ2) Negative/low N (%) Positive/high N (%) p-value (χ2) 
ER 
Negative 
Positive 
 
210 (74.7) 
313 (37.0) 
 
71 (25.3) 
533 (63.0) 
 
<0.001 (120.77) 
- - - - - - 
PgR 
Negative 
Positive 
 
280 (64.4) 
229 (34.8) 
 
155 (35.6) 
429 (65.2) 
 
<0.001 (92.00) 
 
78 (47.0) 
229 (34.8) 
 
88 (53.0) 
429 (65.2) 
 
0.004 (8.48) 
- - - 
HER2 
Negative 
Positive 
 
425 (44.8) 
82 (58.2) 
 
523 (55.2) 
59 (41.8) 
 
0.003 (8.76) 
 
269 (36.0) 
35 (48.6) 
 
479 (64.0) 
37 (51.4) 
 
0.034 (4.50) 
 
153 (79.3) 
47 (68.1) 
 
40 (20.7) 
22 (31.9) 
 
0.061 (3.50) 
BC Molecular Class 
Luminal 
HER2-positive 
TN Non-Basal 
TN Basal-like 
 
279 (35.9) 
83 (58.5) 
43 (89.6) 
109 (76.8) 
 
499 (64.1) 
59 (41.5) 
5 (10.4) 
33 (23.2) 
 
 
<0.001 (131.69) 
 
278 (35.8) 
35 (48.6) 
- 
- 
 
498 (64.2) 
37 (51.4) 
- 
- 
 
 
0.034 (4.63) 
 
- 
48 (68.6) 
43 (89.6) 
109 (76.80 
 
- 
22 (31.4) 
5 (10.4) 
33 (23.2) 
 
 
0.049 (7.85) 
AGTR1 
Negative 
Low 
Positive 
 
64 (43.8) 
77 (41.2) 
167 (55.5) 
 
82 (56.2) 
110 (58.8) 
134 (44.5) 
 
 
0.004 (11.16) 
 
30 (28.6) 
51 (34.7) 
94 (44.5) 
 
75 (71.4) 
96 (65.3) 
117 (55.5) 
 
 
0.014 (8.50) 
 
34 (82.9) 
26 (66.7) 
73 (81.1) 
 
7 (17.1) 
13 (33.3) 
17 (18.9) 
 
0.133 (4.03) 
PELP1  
Negative 
Low 
High 
 
46 (36.8) 
245 (48.9) 
58 (44.6) 
 
79 (63.2) 
256 (51.1) 
72 (55.4) 
 
 
0.049 (6.05) 
 
28 (28.0) 
152 (39.9) 
25 (28.7) 
 
72 (72.0) 
229 (60.1) 
62 (71.3) 
 
 
0.026 (7.27) 
 
18 (75.0) 
93 (78.2) 
33 (76.7) 
 
6 (25.0) 
26 (21.8) 
10 (23.3) 
 
0.91 (0.19) 
 
CARM1 
Negative 
Low 
Positive 
 
102 (52.8) 
168 (43.9) 
79 (51.3) 
 
91 (47.2) 
215 (56.1) 
75 (48.7) 
 
 
0.078 (5.11) 
 
77 (47.2) 
97 (33.9) 
30 (31.6) 
 
86 (52.8) 
189 (66.1) 
65 (68.4) 
 
 
0.008 (9.59) 
 
24 (85.7) 
71 (74.0) 
50 (82.0) 
 
4 (14.3) 
25 (26.0) 
11 (18.0) 
 
0.292 (2.46) 
CD71 
Negative 
Positive  
 
128 (39.0) 
244 (55.6) 
 
200 (61.0) 
195 (44.4) 
 
<0.001 (20.60) 
 
93 (33.2) 
124 (43.1) 
 
187 (66.8) 
164 (56.9) 
 
0.016 (5.82) 
 
35 (74.5) 
119 (80.4) 
 
12 (25.5) 
29 (19.6) 
 
0.099 (4.63) 
Cyclin B1 
Negative 
Positive 
 
179 (47.1) 
126 (47.2) 
 
201 (52.9) 
141 (52.8) 
 
0.983 (0.00) 
 
99 (35.7) 
70 (37.0) 
 
178 (64.3) 
119 (63.0) 
 
0.775 (0.08) 
 
80 (78.4) 
56 (71.8) 
 
22 (21.6) 
22 (28.2) 
 
0.938 (0.13) 
FOXa1 
Negative 
Positive 
 
255 (62.0) 
104 (31.3) 
 
156 (38.0) 
228 (68.7) 
 
<0.001 (69.40) 
 
124 (49.8) 
82 (27.8) 
 
125 (50.2) 
213 (72.2) 
<0.001 (27.78)  
131 (80.9) 
22 (61.1) 
 
31 (19.1) 
14 (38.9) 
 
0.250 (2.78) 
GATA3 
Negative/Low 
Positive 
 
280 (56.9) 
43 (27.9) 
 
212 (43.1) 
111 (72.1) 
 
<0.001 (39.42) 
 
144 (45.0) 
42 (28.0) 
 
176 (55.0) 
108 (72.0) 
<0.001 (12.34)  
136 (79.1) 
0 (0.0) 
 
36 (20.9) 
1 (100.0) 
 
0.250 (0.76) 
P53 
Negative 
Positive 
 
331 (42.5) 
168 (55.3) 
 
448 (57.5) 
136 (44.7) 
 
<0.001 (14.36) 
 
235 (36.0) 
63 (68.9) 
 
418 (64.0) 
99 (61.1) 
0.493 (0.47)  
95 (76.6) 
105 (73.9) 
 
29 (23.4) 
37 (26.1) 
 
0.305 (1.05) 
TK1 
Negative 
Positive 
 
109 (38.0) 
162 (49.5) 
 
178 (62.0) 
165 (50.5)) 
 
0.004 (8.29) 
 
78 (31.2) 
78 (36.6) 
 
172 (68.8) 
135 (63.4) 
0.219 (1.51)  
31 (86.1) 
84 (73.7) 
 
5 (13.9) 
30 (26.3) 
 
0.011 (6.54) 
BEX1 
Negative/Low 
Positive 
 
144 (60.0) 
202 (42.6) 
 
96 (40.0) 
272 (57.4) 
 
<0.001 (19.28) 
 
91 (53.5) 
112 (31.3) 
 
79 (46.5) 
246 (68.7) 
<0.001 (24.10)  
53 (76.8) 
89 (78.1) 
 
16 (23.2) 
25 (21.9) 
 
0.055 (3.70) 
RERG 
Negative 
Positive 
 
282 (49.8) 
63 (33.2) 
 
284 (50.2) 
127 (66.8) 
 
<0.001 (15.92) 
 
162 (38.8) 
37 (24.7) 
 
255 (61.2) 
113 (75.3) 
0.002 (9.74)  
120 (81.6) 
26 (65.0) 
 
27 (18.4) 
14 (35.0) 
 
0.615 (0.25) 
Ki67 
Negative 
Positive 
 
126 (34.5) 
292 (53.1) 
 
239 (65.5) 
258 (46.9) 
 
<0.001 (30.49) 
 
107 (32.3) 
144 (40.3) 
 
224 (67.7) 
213 (59.7) 
0.029 (4.76)  
19 (61.3) 
147 (76.6) 
 
12 (38.7) 
45 (23.4) 
 
0.124 (2.36) 
 
Table 3: Cox proportional hazard analysis for predictors of BCSS within 
the whole series and ER+ tumours for the expression AR and other co-
variates:  
 
 
Variable 
In the whole series In ER positive tumours 
p value HR 95% CI p value HR 95% CI 
AR   0.033 0.80 0.64-0.98 0.007 0.71 0.56-0.91 
Tumour size 0.011 1.33 1.07-1.66 0.003 1.49 1.15-1.94 
Nodal Stage <0.001 1.80 1.55-2.08 <0.001 1.62 1.35-1.94 
Tumour grade <0.001 1.61 1.36-1.91 <0.001 1.72 1.42-2.07 
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Supplementary Table 1: Clinico-pathological features of the study 
cohort:  
Clinicopathological 
characteristics 
 
N (%)* 
Age 
≤50 
>50 
Missing 
416 (41.9) 
578 (58.1) 
147 
Menopausal Status 
Pre-menopausal  
Post- menopausal 
Missing  
410 (41.6) 
576 (58.4) 
155 
Tumour Size (cm) 
≤2.0 
>2.0 
Missing 
474 (47.8) 
518 (52.2) 
149 
Tumour Type 
Ductal NST 
Lobular 
Tubular mixed  
Medullary-like 
Special types 
Mixed NST and Lobular 
Mixed NST and other special type 
Missing 
671 (60.2) 
108 (9.7) 
196 (17.6) 
25 (2.2) 
50 (4.5) 
44 (3.9) 
20 (1.8) 
27 
NPI** 
GPG 
MPG 
PPG 
Missing 
284 (28.6) 
535 (53.9) 
173 (17.4) 
149 
Stage 
1 
2 
3 
Missing 
603 (60.9) 
306 (30.9) 
81 (8.2) 
151 
Grade 
1 
2 
3 
Missing 
153 (15.5) 
324 (32.7) 
513 (51.8) 
151 
LVI 
Negative 
Definite 
Missing  
635 (64.3) 
352 (35.7) 
154 
Distant metastases 
No 
Yes 
Missing  
626 (63.3) 
363 (36.7) 
152 
BC Molecular classes  
Luminal  
HER2 positive  
Triple negative (TN) non-Basal 
TN Basal-like  
Missing 
778 (68.2) 
142 (12.4) 
48 (4.2) 
142 (12.4) 
31 
* These are the valid percentages (excluding the missing cases for each
parameter). 
** NPI: Nottingham Prognostic Index, GPG; Good Prognostic Group; MPG: 
Moderate Prognostic Group; PPG: Poor Prognostic Group; LVI: Lympho-Vascular 
Invasion.  
Supplementary Table 2: The prognostic impact AR mRNA in the external validation cohorts using bc-GenExMiner v4.0 for publicly available 
online datasets (n=25 datasets, 4078 patients).   
*: High AR mRNA associated is good prognostic, **: Low AR mRNA is poor prognostic. HR: Hazard Ratio, CI: confidence Interval. 
Cohort Reference p-value HR 95% CI 
Number 
of 
patients 
Number of 
Metastatic 
Recurrence 
Rosetta2002 Van de Vijver et al., 2002 0.0283* 0.81 0.67 - 0.98 295 101 
GSE2603 Minn et al., 2005 0.1730 0.76 0.51 - 1.13 82 27 
GSE1456 Pawitan et al., 2005 0.0081* 0.68 0.51 - 0.90 159 40 
GSE2034 Wang et al., 2005 0.2240 0.89 0.73 - 1.08 286 107 
GSE2741 Weigelt et al., 2005 0.9326 0.98 0.57 - 1.67 50 13 
E_TABM_158 Chin et al., 2006 0.4500 0.85 0.56 - 1.29 112 21 
GSE8757 Chin et al., 2007 0.4197 1.17 0.80 - 1.72 171 38 
GSE7390 Desmedt et al., 2007 0.9975 1.00 0.78 - 1.28 198 62 
GSE6532 Loi et al., 2007 0.8289 0.98 0.79 - 1.20 393 101 
GSE5327 Minn et al., 2007 0.3105 0.70 0.35 - 1.39 58 11 
GSE7378 Zhou et al., 2007 0.4463 1.35 0.62 - 2.96 54 9 
GSE7849 Anders et al., 2008 0.7200 1.11 0.63 - 1.97 75 14 
GSE9893 Chanrion et al., 2008 < 0.0001** 1.65 1.32 - 2.07 155 48 
GSE9195 Loi et al., 2008 0.4475 1.37 0.61 - 3.06 77 10 
GSE11121 Schmidt et al., 2008 0.2548 0.85 0.65 - 1.12 200 46 
GSE11264 Jézéquel et al., 2009 0.0086* 0.74 0.58 - 0.92 252 65 
GSE12093 Zhang et al., 2009 0.2807 0.77 0.48 - 1.24 136 20 
GSE19615 Li et al., 2010 0.5784 0.86 0.50 - 1.47 115 14 
GSE17907 Sircoulomb et al., 2010 0.4559 1.24 0.70 - 2.21 39 17 
GSE22219 Buffa et al., 2011 0.3434 0.90 0.73 - 1.12 216 82 
GSE26971 Filipits et al., 2011 0.0006* 0.69 0.56 - 0.86 258 58 
GSE25055 Hatzis et al., 2011 < 0.0001* 0.60 0.49 - 0.74 309 65 
GSE20685 Kao et al., 2011 0.7064 0.95 0.75 - 1.22 296 63 
GSE33926 Kuo et al., 2012 0.1419 1.49 0.87 - 2.55 51 12 
GSE45255 Nagalla et al., 2013 0.2755 0.74 0.43 - 1.27 41 14 
Pooled Data < 0.0001* 0.88 0.83 - 0.94 4078 1058 
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